Organization | Science Valley Research Institute

Science Valley Research Institute Report issue

For profit Phase 2 Phase 3 Phase 4

Founded: São Paulo Brazil (2015)

Organization Overview

First Clinical Trial

2020

NCT04229264

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

André Luiz Malavasi Longo de Oliveira | Samantha Rodrigues Camargo Neves de Moura | Science Valley Research Institute | Tânia Portella Costa

Active Ingredients

Drugs in Phase 4 Trials (1)

rivaroxaban (xarelto) (3 trials)

Drugs in Phase 3 Trials (7)

acetylsalicylic acid (aspirin) (1 trial)

aldesleukin (Proleukin) (1 trial)

apixaban (eliquis) (1 trial)

clopidogrel (plavix) (1 trial)

colchicine (colbenemid) (1 trial)

enoxaparin (lovenox) (1 trial)

ixekizumab (taltz) (1 trial)

Drugs in Phase 2 Trials (2)

COVID-19 convalescent plasma (1 trial)

oxybutynin (ditropan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Ischemia (Phase 3)

Thromboembolism (Phase 3)

Thrombosis (Phase 3)

Venous Thromboembolism (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 7
# of Trial APIs: 10